Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Rous Sarcoma Virus (RSV) and Cancer

Rous Sarcoma Virus (RSV) and Cancer

Rous Sarcoma virus or RSV was discovered by F. Peyton Rous in the year 1911 as a filterable transmissible agent that could cause tumors in chickens. He won a Nobel Prize for this discovery in 1966. His experiments clearly demonstrated that some cancers could be caused by infectious agents and led to the discovery of many more cancer-causing viruses in animals as well as humans.
RSV is a retrovirus that contains two copies of a plus-strand RNA genome. Its genome consists of four main open...

Rous Sarcoma Virus (RSV) and Cancer

Rous Sarcoma Virus (RSV) and Cancer

Tumor Progression

Tumor Progression

Tumor progression is a phenomenon where the pre-formed tumor acquires successive mutations to become clinically more aggressive and malignant. In the 1950s, Foulds first described the stepwise progression of cancer cells through successive stages.
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Fibroblast growth factor receptor inhibition for succinate dehydrogenase-deficient gastrointestinal stromal tumors: a phase 2 trial.

Nature medicine·2026

Same author

NCCN Guidelines® Insights: Soft Tissue Sarcoma, Version 1.2025.

Journal of the National Comprehensive Cancer Network : JNCCN·2026

Same author

Olutasidenib in recurrent/relapsed locally advanced or metastatic IDH1-mutated chondrosarcoma: phase 1b/2 trial.

Nature communications·2026

Same author

SARC031: A Phase II Trial of Selumetinib and Sirolimus for Patients with Unresectable or Metastatic Malignant Peripheral Nerve Sheath Tumors (MPNST).

Clinical cancer research : an official journal of the American Association for Cancer Research·2026

Same author

A plain language summary of the AMPECT study: nab-sirolimus for advanced malignant perivascular epithelioid cell tumors.

Future oncology (London, England)·2025

Same author

Replication-Competent, Tumor-Specific Immuno-Gene Vectors Allow for Exchange of Transgenes and Lead to Viral Persistence Following IV Administration.

Journal of immunotherapy and precision oncology·2025

Same journal

Measuring Equitable Care Delivery: Insights From the Health Equity Report Card (HERC) Pilot in Academic Cancer Centers.

Journal of the National Comprehensive Cancer Network : JNCCN·2026

Same journal

A Virtual Reality Psychosocial Intervention for Patients Undergoing Bone Marrow Transplantation (BMT-VR): Pilot Randomized Clinical Trial.

Journal of the National Comprehensive Cancer Network : JNCCN·2026

Same journal

Nationwide Trends in Colorectal Cancer Screening by the End of the COVID-19 Pandemic: Racial/Ethnic Differences and Opportunities.

Journal of the National Comprehensive Cancer Network : JNCCN·2026

Same journal

Evaluation of the Impact of Adjuvant Immunotherapy in Merkel Cell Carcinoma.

Journal of the National Comprehensive Cancer Network : JNCCN·2026

Same journal

Payers' Views on Insurance Coverage for Confirmatory Diagnostics After a Noncovered Multicancer Early Detection (MCED) Test.

Journal of the National Comprehensive Cancer Network : JNCCN·2026

Same journal

Surrogacy of Intermediate Clinical Endpoints for Overall Survival in Patients With Localized Muscle-Invasive Bladder Cancer.

Journal of the National Comprehensive Cancer Network : JNCCN·2026

See all related articles

Search research articles

Related Experiment Video

Updated: May 1, 2026

A Mouse Model of Incompletely Resected Soft Tissue Sarcoma for Testing Neoadjuvant Therapies

A Mouse Model of Incompletely Resected Soft Tissue Sarcoma for Testing Neoadjuvant Therapies

Published on: July 28, 2020

Soft tissue sarcoma, version 2.2014.

Margaret von Mehren¹, R Lor Randall, Robert S Benjamin

¹From 1Fox Chase Cancer Center; 2Huntsman Cancer Institute at the University of Utah; 3The University of Texas MD Anderson Cancer Center; 4UC San Diego Moores Cancer Center; 5Moffitt Cancer Center; 6Memorial Sloan-Kettering Cancer Center; 7Fred Hutchinson Cancer Research Center/Seattle Cancer Care Alliance; 8Massachusetts General Hospital Cancer Center; 9Stanford Cancer Institute; 10Dana-Farber/Brigham and Women's Cancer Center; 11University of Alabama at Birmingham Comprehensive Cancer Center; 12Roswell Park Cancer Institute; 13The Ohio State University Comprehensive Cancer Center - James Cancer Hospital and Solove Research Institute; 14Fred & Pamela Buffett Cancer Center at The Nebraska Medical Center; 15The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins; 16UCSF Helen Diller Family Comprehensive Cancer Center; 17St. Jude Children's Research Hospital/The University of Tennessee Health Science Center; 18City of Hope Comprehensive Cancer Center; 19Siteman Cancer Center at Barnes-Jewish Hospital and Washington University School of Medicine; 20Duke Cancer Institute; 21University of Michigan Comprehensive Cancer Center; 22Vanderbilt-Ingram Cancer Center; 23Robert H. Lurie Comprehensive Cancer Center of Northwestern University; and 24National Comprehensive Cancer Network.

Journal of the National Comprehensive Cancer Network : JNCCN

|April 11, 2014

Summary

This summary is machine-generated.

NCCN updates now include radiation therapy guidance for retroperitoneal soft tissue sarcoma (STS). Genetic testing and counseling recommendations are also added for patients with hereditary cancer syndromes.

More Related Videos

Establishment of a Primary Culture of Patient-derived Soft Tissue Sarcoma

Establishment of a Primary Culture of Patient-derived Soft Tissue Sarcoma

Published on: April 11, 2018

Three-Dimensional Bone Extracellular Matrix Model for Osteosarcoma

Three-Dimensional Bone Extracellular Matrix Model for Osteosarcoma

Published on: April 12, 2019

Related Experiment Videos

Last Updated: May 1, 2026

A Mouse Model of Incompletely Resected Soft Tissue Sarcoma for Testing Neoadjuvant Therapies

A Mouse Model of Incompletely Resected Soft Tissue Sarcoma for Testing Neoadjuvant Therapies

Published on: July 28, 2020

Establishment of a Primary Culture of Patient-derived Soft Tissue Sarcoma

Establishment of a Primary Culture of Patient-derived Soft Tissue Sarcoma

Published on: April 11, 2018

Three-Dimensional Bone Extracellular Matrix Model for Osteosarcoma

Three-Dimensional Bone Extracellular Matrix Model for Osteosarcoma

Published on: April 12, 2019

Area of Science:

Oncology
Medical Guidelines

Background:

Soft tissue sarcoma (STS) management requires updated clinical guidance.
Retroperitoneal/intra-abdominal STS presents unique treatment challenges.

Purpose of the Study:

To summarize recent NCCN Guidelines updates for Soft Tissue Sarcoma (STS).
To highlight changes in radiation therapy recommendations for retroperitoneal/intra-abdominal STS.
To outline new guidelines for genetic testing in STS patients.

Main Methods:

Review of NCCN Guidelines for Soft Tissue Sarcoma.
Analysis of updated recommendations regarding radiation therapy.
Inclusion of new guidance on genetic counseling and testing.

Main Results:

Updated NCCN Guidelines provide specific recommendations for radiation therapy in retroperitoneal/intra-abdominal STS.
Guidelines now incorporate genetic testing and counseling for patients with a history of hereditary cancer syndromes predisposing to STS.

Conclusions:

The updated NCCN Guidelines offer crucial advancements in managing retroperitoneal/intra-abdominal STS.
Emphasis on genetic evaluation is important for patients with a predisposition to STS.